Compare BioNTech SE - ADR (BNTX) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Vanguard S&P 500 ETF — how do they compare? BioNTech SE - ADR trades at $90.29 (market cap $22.86B), while Vanguard S&P 500 ETF trades at $692.53. The key difference: Vanguard S&P 500 ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | VOO | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $119.34 | $698.29 |
52-Week Low | $83.89 | $571.45 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
VOO, the Vanguard S&P 500 ETF, trades at $688.55, down 0.76% over the past day. Technical indicators show a bullish moving average trend but neutral oscillators, with support near $686 and resistance at $692. The ETF provides diversified exposure to large-cap U.S. stocks, with a dividend of $1.96 scheduled for June 2026. Recent news highlights ongoing discussions about S&P 500 valuations and potential market catalysts from earnings season.
Outlook remains tied to broad market performance, with analysts projecting further S&P 500 gains amid economic resilience. Risks include market volatility and high valuations. The ETF offers a low-cost, passive investment avenue, but investors should monitor macroeconomic trends and earnings results for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
